NCT06883357 The Effects of Home-based Graded Repetitive Arm Supplementary Program Group on Stroke.
| NCT ID | NCT06883357 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 52 participants |
| Start Date | 2025-03-17 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 52 participants in total. It began in 2025-03-17 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Graded repetitive arm supplementary program (GRASP) is a self administrated, home-based rehabilitation program and has been incorporated in Canadian Stroke Best Practice Recommendations. Past studies indicated that the home-based GRASP program could facilitate the motor function and motor recovery and prevent learned nonuse of affected upper limb of stroke patients. There is lacking of research and application of the home-based GRASP program in Taiwan. Therefore, this study aims to explore the effects of the home-based GRASP program, which is mainly executed in the form of group intervention, on the affected upper limb of stroke patients.
Eligibility Criteria
Inclusion Criteria: 1. Age is above 20 years old. 2. Onset of first stroke complicated with hemiplegia or hemiparesis. 3. The affected upper limb remains partially voluntary movements including lifting to chest level and holding for five seconds; slight flexion and extension of wrist and hand. 4. Understanding and complying with two-steps commands. 5. Understanding the content of trial and willing to sign informed consent. Exclusion Criteria: 1. Complicating with other neurological disease. 2. Having Orthopedic diseases affecting the movements of upper limbs. 3. Having symptoms of pain to affect the movements of upper limbs. 4. Unstable vital sign or medical condition. 5. Participating another rehabilitative or drug research meanwhile. 6. Receiving botulinum toxin injection within three months.
Contact & Investigator
Chia-Yi Lin
STUDY DIRECTOR
Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital Hsin-Chu Branch
Frequently Asked Questions
Who can join the NCT06883357 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06883357 currently recruiting?
Yes, NCT06883357 is actively recruiting participants. Contact the research team at G04812@hch.gov.tw for enrollment information.
Where is the NCT06883357 trial being conducted?
This trial is being conducted at Hsinchu, Taiwan.
Who is sponsoring the NCT06883357 clinical trial?
NCT06883357 is sponsored by National Taiwan University Hospital. The principal investigator is Chia-Yi Lin at Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital Hsin-Chu Branch. The trial plans to enroll 52 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.